Saturday 17 October 2026
Export TYRA’s income statement to Excel — free account
Tyra Biosciences, Inc.
TYRA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 46.8% and free cash flow fell 31.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
18.52
0.52
−2.73%
Follow TYRA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(34.75%) | (39.83%) | (36.87%) | (45.31%) | |
| (32.73%) | (37.13%) | (34.71%) | (42.15%) | ||
ROIC |
(1,409.64%) | (2,614.25%) | (2,173.73%) | 0.00% | |
Return on Tangible Assets |
(41.88%) | (48.24%) | (34.82%) | (43.25%) | |
Free Cash Flow per Share |
(1.53) | (1.60) | (1.66) | (1.67) | |
Free Cash Flow |
(91.20) | (95.28) | (102.47) | (109.90) | |
Capital Expenditures |
(0.09) | (0.14) | (0.21) | (0.25) | |
| Other line items | |||||
Cash ROIC |
(16.42%) | (18.50%) | (13.29%) | (15.53%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.82 | 0.79 | 0.78 | 0.74 | |
Depreciation/Fixed assets |
0.41 | 0.42 | 0.45 | 0.46 | |
Capex/Depreciation |
(0.16) | (0.26) | (0.40) | (0.46) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.53) | (1.60) | (1.66) | (1.66) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates